Neurofibromatosis Treatment Market Report 2026

Neurofibromatosis Treatment Market Overview

• Neurofibromatosis Treatment market size has reached to $14.83 billion in 2025 • Expected to grow to $27.75 billion in 2030 at a compound annual growth rate (CAGR) of 13.5% • Growth Driver: Growth Of The Neurofibromatosis Treatment Market Driven By Rising R&D Activities • Market Trend: Neurofibromatosis Treatment With New Drug Application for Mirdametinib • North America was the largest region in 2025.

What Is Covered Under Neurofibromatosis Treatment Market?

Neurofibromatosis treatment refers to the treatment of a genetic disorder that causes tumors to grow on nerve tissue, which can form anywhere in the body, including the brain, spinal cord and nerves. Neurofibromatosis treatment is used to manage symptoms, slow down the progression of the disease and prevent complications. The neurofibromatosis treatment is used to treat neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2) and schwannomatosis. Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the development of tumors on nerves throughout the body. The types of treatments include medications, surgery, radiation therapy and others, which are used by several end-users, including hospitals, clinics and others.

What Is The Neurofibromatosis Treatment Market Growth Forecast?

The neurofibromatosis treatment market size is expected to see rapid growth in the next few years. It will grow to $27.75 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to growing demand for precision oncology treatments, increasing availability of genetic testing tools, rising investment in tumor-targeting drug development, expansion of minimally invasive surgical options, development of novel pain management solutions. Major trends in the forecast period include increasing use of targeted drug therapy for tumor reduction, rising adoption of surgical treatment for complication management, growing demand for radiation therapy in nf2 cases, expansion of genetic counseling and early detection programs, increasing focus on pain management and symptom control.

Global Neurofibromatosis Treatment Market Segmentation

1) By Type: Neurofibromatosis 1 (NF1), Neurofibromatosis 2 (NF2), Schwannomatosis 2) By Treatment: Medications, Surgery, Radiation Therapy, Other Treatments 3) By End-User: Hospitals, Clinics, Other End Users Subsegments: 1) By Neurofibromatosis 1 (NF1): Surgical Interventions, Medication for Symptom Management, Genetic Counseling 2) By Neurofibromatosis 2 (NF2): Surgical Interventions, Radiation Therapy, Medication For Symptom Management 3) By Schwannomatosis: Surgical Interventions, Pain Management Therapies, Genetic Counseling

What Is The Driver Of The Neurofibromatosis Treatment Market?

The increasing research and development (R&D) activities are expected to boost the growth of the neurofibromatosis treatment market going forward. Research and development (R&D) activities refer to systematic, purpose-driven efforts undertaken to discover new knowledge, develop innovative technologies, and advance products or services through scientific inquiry and technical experimentation. A key factor driving the increase in research and development activities is the growing demand for more effective, targeted medical solutions, which encourages organizations to invest in novel scientific approaches that can address unmet clinical needs and improve long-term health outcomes. In this context, advancements in neurofibromatosis treatment reinforce the momentum of rising research and development activities by demonstrating the value of continued innovation in complex disease areas and motivating further exploration of therapeutic breakthroughs. For instance, in April 2025, according to the Office for National Statistics, a UK-based statistics authority, the UK government’s net research and development expenditure increased to £17.4 billion ($21.8 billion) in 2023 from £16.1 billion ($20.1 billion) in 2022, reflecting an 8.2% rise. Therefore, the increasing research and development (R&D) activities are driving the growth of the neurofibromatosis treatment industry.

Key Players In The Global Neurofibromatosis Treatment Market

Major companies operating in the neurofibromatosis treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Vertex Pharmaceuticals Inc., BioMarin Pharmaceutical, BioXcel Therapeutics Inc., Blueprint Medicines Corp., SpringWorks Therapeutics, Affymax Inc., NFlection Therapeutics Inc., Mulberry Biotherapeutics, CureAge Therapeutics, Recursion Pharmaceuticals, Vivace Therapeutics, Healx Limited, NF2 Therapeutics Inc.

Global Neurofibromatosis Treatment Market Trends and Insights

Major companies operating in the neurofibromatosis treatment market are developing innovative drugs and investigational targeted therapies such as MEK inhibitors to sustain their position in the market. A MEK inhibitor refers to a class of targeted therapies that block the MEK enzyme, part of the MAPK signaling pathway, to help treat cancers and genetic disorders such as neurofibromatosis by inhibiting cell growth and tumor progression. For instance, in March 2024, SpringWorks Therapeutics, Inc., a US-based biopharmaceutical company, finalized its submission of a new drug application to the FDA for Mirdametinib, aimed at treating both children and adults with NF1-PN. Mirdametinib is a selective MEK inhibitor designed to target specific pathways involved in the growth of neurofibromas. The FDA's review process will evaluate the safety and efficacy of this treatment, with the potential to significantly improve outcomes for individuals suffering from NF1-PN.

What Are Latest Mergers And Acquisitions In The Neurofibromatosis Treatment Market?

In July 2025, Merck KGaA, a Germany-based science and technology company, acquired SpringWorks Therapeutics for $3.4 billion. With this acquisition, Merck KGaA aims to expand its rare tumor portfolio and strengthen its global oncology strategy by integrating SpringWorks’ FDA-approved therapies for desmoid tumors and neurofibromatosis type 1–related plexiform neurofibromas. SpringWorks Therapeutics is a US-based provider of targeted therapies for rare tumors and genetically defined cancers, including approved treatments for desmoid tumors and NF1-associated plexiform neurofibromas.

Regional Outlook

North America was the largest region in the neurofibromatosis treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neurofibromatosis Treatment Market?

The neurofibromatosis treatment market consists of revenues earned by entities by providing services such as stereotactic radiosurgery, genetic evaluation, physical therapy and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurofibromatosis treatment market also includes sales of drugs such as selumetinib, bevacizumab and tricyclic antidepressants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neurofibromatosis Treatment Market Report 2026?

The neurofibromatosis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neurofibromatosis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.